Blog
RSS FeedPosted by Michael Wonder on 05 Mar 2024
New treatment option available today for womb cancer
5 March 2024 - A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent ...
Posted by Michael Wonder on 06 Jun 2023
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
6 June 2023 - NICE has published evidence-based recommendations for daratumumab (Darzalex) for use in combination with bortezomib and dexamethasone ...
Posted by Michael Wonder on 11 Nov 2022
Cannabidiol for the treatment of patients with seizures caused by tuberous sclerosis complex
8 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 19 Apr 2022
Supply related data in manufacturer dossiers: things are not going smoothly yet
19 April 2022 - The criteria for supply related data established by IQWiG in 2020 were positively received in science. ...
Posted by Michael Wonder on 23 Mar 2022
Acceptability of manufacturer proposed utility values for NICE cancer medicine appraisals: analysis of manufacturers’ information sources
21 March 2022 - The NICE method guide for technology appraisals encourages medicine manufacturers to use the EuroQol 5 Dimension in ...
Posted by Michael Wonder on 09 Mar 2022
Time to ask companies why they don’t submit to NICE?
9 March 2022 - Companies can choose whether or not to submit to NICE to have their products appraised. ...
Posted by Michael Wonder on 22 Feb 2022
Does the DoH favour some pharmaceutical companies over others?
23 February 2022 - Some interesting insights from version 1 of the agenda for the May 2022 PBAC (intracycle) meeting. ...
Posted by Michael Wonder on 06 Apr 2021
Agenda for the July 2021 PBAC meeting
6 April 2021 - How long will we have to wait for version 2? ...
Posted by Michael Wonder on 21 May 2019
Official Information Act response: adrenaline auto-injector cost utility analysis
20 May 2019 - PHARMAC responds to a request for any cost utility analyses performed by PHARMAC in relation to ...